My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 215

    1.

    Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.

    Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M.

    Diabetes. 2004 Jun;53(6):1621-9. Erratum in: Diabetes. 2005 Feb;54(2):587. PMID: 15161771 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

    Diabetes. 2002 Oct;51(10):2968-74.PMID: 12351435 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle.

    Li W, Tonelli J, Kishore P, Owen R, Goodman E, Scherer PE, Hawkins M.

    Am J Physiol Endocrinol Metab. 2007 May;292(5):E1301-7. Epub 2007 Jan 9. Erratum in: Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E402. PMID: 17213476 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The ratio of leptin to adiponectin can be used as an index of insulin resistance.

    Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M.

    Metabolism. 2008 Feb;57(2):268-73.PMID: 18191059 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.

    Boden G, Cheung P, Mozzoli M, Fried SK.

    Metabolism. 2003 Jun;52(6):753-9.PMID: 12800103 [PubMed - indexed for MEDLINE]Related articles

    8.

    Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.

    Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.

    Diabetologia. 2009 Apr;52(4):723-32. Epub 2009 Jan 24.PMID: 19169664 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

    Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K.

    Diabetes Care. 2003 Sep;26(9):2493-9.PMID: 12941708 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.

    Hammarstedt A, Pihlajamäki J, Graham TE, Kainulainen S, Kahn BB, Laakso M, Smith U.

    J Intern Med. 2008 Apr;263(4):440-9.PMID: 18324929 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.

    Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T.

    Diabet Med. 2007 Sep;24(9):962-8. Epub 2007 May 17.PMID: 17509067 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

    Metabolism. 2007 Oct;56(10):1418-24.PMID: 17884455 [PubMed - indexed for MEDLINE]Related articles

    15.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The effect of pioglitazone on the liver: role of adiponectin.

    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.

    Diabetes Care. 2006 Oct;29(10):2275-81.PMID: 17003306 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

    Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T.

    Metabolism. 2002 Mar;51(3):314-7.PMID: 11887166 [PubMed - indexed for MEDLINE]Related articles

    18.

    Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.

    Diabetes. 2008 Jan;57(1):24-31. Epub 2007 Oct 3.PMID: 17914032 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

    Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.

    Diabetes Care. 2008 Jan;31(1):121-7. Epub 2007 Oct 1.PMID: 17909084 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.

    Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T.

    J Biol Chem. 2006 Mar 31;281(13):8748-55. Epub 2006 Jan 23.PMID: 16431926 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity